← REGULATORY CHANGES
FEDERAL REGISTER · RULESeptember 5, 2024IN FORCE

Medical Devices; Hematology and Pathology Devices; Classification of the Heparin and Direct Oral Factor Xa Inhibitor Drug Test System

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSIN FORCE
EFFECTIVESep 5, 2024
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGDrugDevice
Document type
Rule
Agency
Health and Human Services Department
Published
September 5, 2024
Effective
September 5, 2024
Document number
2024-19824
CFR references
21 CFR 864
Docket
FDA-2024-N-3971
ABSTRACT

The Food and Drug Administration (FDA or we) is classifying the heparin and direct oral factor Xa inhibitor drug test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the heparin and direct oral factor Xa inhibitor drug test system's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices.

Abstract as published in the Federal Register.